---
schema_version: "secwatch.filing_event.v1"
accession: "0000917520-24-000017"
form_type: "8-K"
ticker: "IART"
cik: "0000917520"
company_name: "INTEGRA LIFESCIENCES HOLDINGS CORP"
filed_at: "2024-02-28T23:59:59+00:00"
generated_at: "2026-06-05T10:14:57.793273+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Integra LifeSciences Q4 GAAP EPS $0.25 vs $0.63; guides FY2024 revenue up 4-5% organic

## Summary
- Q4 revenues $397.0M, down 0.2% reported; organic revenue ex-Boston up 3.6%.
- GAAP EPS $0.25, adjusted EPS $0.89 vs $0.94 prior year.
- Full-year 2023 adjusted EPS $3.10 vs $3.36; Boston relaunch on track for mid-to-late Q2 2024.
- Signed definitive agreement to acquire Acclarent ENT business expected to close by Q2 2024.
- FY2024 guidance: revenue $1,603M-$1,618M (organic +4-5%), adjusted EPS $3.15-$3.25.

## SEC filing metadata
- accession: 0000917520-24-000017
- form_type: 8-K
- ticker: IART
- cik: 0000917520
- company_name: INTEGRA LIFESCIENCES HOLDINGS CORP
- filed_at: 2024-02-28T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/917520/000091752024000017/0000917520-24-000017-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/917520/000091752024000017/iart-20240228.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000917520-24-000017
- JSON: https://secwatch.observer/filing/0000917520-24-000017.json
- Plain text: https://secwatch.observer/filing/0000917520-24-000017.txt

## Key facts
- Earnings Releases
  INTEGRA LIFESCIENCES HOLDINGS CORP reported full-year 2024 results: revenue $1,603 million to $1,618 million, EPS $3.15 to $3.25. Guidance initiated.
  - Period: full-year 2024
  - Revenue: $1,603 million to $1,618 million
  - EPS: $3.15 to $3.25
  - Guidance: initiated
  - Result: guidance update
  source text: For the full-year 2024, the Company expects revenues to be in a range of $1,603 million to $1,618 million, representing reported growth of approximately 4.0% to 5.0% and organic growth in the range of 4.0% to 5.0%. Adjusted earnings per diluted share are expected to be between $3.15 and $3.25.
  evidence_url: https://www.sec.gov/Archives/edgar/data/917520/000091752024000017/0000917520-24-000017-index.htm
- Earnings Releases
  INTEGRA LIFESCIENCES HOLDINGS CORP reported full-year 2023 results: revenue $1,541.6 million, net income $67.7 million, EPS $0.84.
  - Period: full-year 2023
  - Revenue: $1,541.6 million
  - Net income: $67.7 million
  - EPS: $0.84
  - Result: reported results
  source text: Total reported revenues for the full-year 2023 were $1,541.6 million, a decrease of 1.0%, from the prior year. Organic sales for the full-year 2023 were flat compared to 2022. Revenue increas ed 5.5% on an organic basis excluding Boston. The Company reported GAAP net income of $67.7 million, or $0.84 per diluted share, for the full-year 2023, compared to GAAP net income of $180.6 million, or $2.16 per diluted share in 2022. Adjusted EBITDA for the full-year 2023 was $369.7 million, a decrease of $41.6 million versus the prior year. Full year EBITDA margins were 24.0% a decrease of 240 basis points from the prior year. Adjusted net income for the full-year 2023 was $247.8 million, or $3.10 per diluted share, compared to $280.9 million, or $3.36 per diluted share.
  evidence_url: https://www.sec.gov/Archives/edgar/data/917520/000091752024000017/0000917520-24-000017-index.htm
- Earnings Releases
  INTEGRA LIFESCIENCES HOLDINGS CORP reported fourth quarter 2023 results: revenue 397.0 million, net income $19.8 million, EPS $0.25.
  - Period: fourth quarter 2023
  - Revenue: 397.0 million
  - Net income: $19.8 million
  - EPS: $0.25
  - Result: reported results
  source text: Total reported revenues for the fourth quarter were 397.0 million, a decrease of 0.2% from the fourth quarter of 2022. Fourth quarter organic revenues were down 1.2% compared to the prior year. Revenue increased 3.6% on an organic basis excluding Boston. The Company reported GAAP net income of $19.8 million, or $0.25 per diluted share, in the fourth quarter of 2023, compared to GAAP net income of $52.9 million, or $0.63 per diluted share, in the prior year. Adjusted EBITDA for the fourth quarter of 2023 was $100.5 million, compared to $109.7 million in the fourth quarter of the prior year. As a percentage of revenue, adjusted EBITDA was 25.3%, a decrease of 230 basis points from the prior year period. Adjusted net income for the fourth quarter of 2023 was $69.1 million, or $0.89 per diluted share, compared to adjusted net income of $78.8 million, or $0.94 per diluted share, in the fourth quarter of 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/917520/000091752024000017/0000917520-24-000017-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.